WESTBROOK, Maine, Nov. 12, 2020 /PRNewswire/ -- IDEXX
Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary
diagnostics, veterinary practice software and water microbiology
testing, announced today the election of Dr. Asha S. Collins, Head of U.S. Clinical
Operations of Genentech, a biotechnology company and member of the
Roche Group, to the Company's Board of Directors, effective
November 11, 2020.
"We are pleased to welcome Asha to the IDEXX Board of
Directors," said Larry Kingsley, the
Company's Board Chair. "Asha is a proven entrepreneur, innovator
and values-based leader in the healthcare field, and we are
confident she will bring a deep scientific understanding, as well
as valuable strategic, operational and management experience at
life science and healthcare companies, to our Board."
"I am excited to join the board of a purpose-driven company that
leads through innovation to enhance the health and well-being of
pets, people and livestock," said Dr. Collins. "I look forward
to working closely with my fellow directors and the IDEXX
leadership team to deliver on our purpose while creating long-term
value for our stakeholders."
Dr. Collins has served as the Head of U.S. Clinical Operations
at Genentech since May 2018. Prior to joining Genentech, Dr.
Collins held several senior leadership positions at McKesson
Corporation between September 2014
and March 2018, including Vice
President of Clinical Sourcing and Business Development from
November 2015 to March 2018 and Senior Director, Corporate
Strategy and Business Development from September 2014 to November
2015. She was previously Principal Consultant at Quintiles
from 2011 to 2014 and Manager at Deloitte Consulting from 2008 to
2011. In July 2019, Dr. Collins was
selected as a Health Innovators Fellow by The Aspen Institute. Dr.
Collins received her Bachelor of Science degree from the
University of Pittsburgh and her PhD in
Cancer Biology and Microbiology from the University of Wisconsin-Madison.
![IDEXX Laboratories, Inc. logo. (PRNewsFoto/IDEXX Laboratories, Inc.) IDEXX Laboratories, Inc. logo. (PRNewsFoto/IDEXX Laboratories, Inc.)](https://mma.prnewswire.com/media/324683/idexx_laboratories__inc__logo.jpg)
About IDEXX Laboratories
IDEXX Laboratories,
Inc. is a member of the S&P 500® Index and
is a leader in pet healthcare innovation, serving practicing
veterinarians around the world with a broad range of diagnostic and
information technology-based products and services. IDEXX products
enhance the ability of veterinarians to provide advanced medical
care, improve staff efficiency, and build more economically
successful practices. IDEXX is also a worldwide leader in providing
diagnostic tests and information for livestock and poultry and
tests for the quality and safety of water and milk and
point-of-care and laboratory diagnostics for human
medicine. Headquartered in Maine, IDEXX employs more than 9,000 people
and offers products to customers in over 175 countries. For
more information about IDEXX, visit: www.idexx.com.
Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be
identified by the use of words such as "expects," "may,"
"anticipates," "intends," "would," "will," "plans," "believes,"
"estimates," "should," "project," and similar words and
expressions. These forward-looking statements are intended to
provide our current expectation or forecasts of future events; are
based on current estimates, projections, beliefs, and assumptions;
and are not guarantees of future performance. Actual events or
results may differ materially from those described in the
forward-looking statements, as well as a number of assumptions
concerning future events. These statements are subject to risks,
uncertainties, assumptions and other important factors. Readers are
cautioned not to put undue reliance on such forward-looking
statements because actual results may vary materially from those
expressed or implied. The reports filed by IDEXX pursuant to
United States securities laws
contain discussions of some of these risks and uncertainties. IDEXX
assumes no obligation to, and expressly disclaims any obligation
to, update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. Readers are
advised to review IDEXX's filings with the United States Securities
and Exchange Commission (which are available from the SEC's EDGAR
database at www.sec.gov and via IDEXX's website at
www.idexx.com).
Contact:
Investor Relations
John Ravis
1-207-556-8155
investorrelations@idexx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/idexx-laboratories-elects-dr-asha-s-collins-to-board-of-directors-301171422.html
SOURCE IDEXX Laboratories, Inc.